These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17893463)

  • 21. The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat.
    Häggkvist J; Lindholm S; Franck J
    Addict Biol; 2009 Jul; 14(3):260-9. PubMed ID: 19298318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone and problems in pain management.
    Vickers AP; Jolly A
    BMJ; 2006 Jan; 332(7534):132-3. PubMed ID: 16424470
    [No Abstract]   [Full Text] [Related]  

  • 23. Electroacupuncture analgesia is mediated by stereospecific opiate receptors and is reversed by antagonists of type I receptors.
    Cheng RS; Pomeranz BH
    Life Sci; 1980 Feb; 26(8):631-8. PubMed ID: 6247596
    [No Abstract]   [Full Text] [Related]  

  • 24. Opiate receptors and their definition by antagonists.
    Yaksh TL; Howe JR
    Anesthesiology; 1982 Apr; 56(4):246-9. PubMed ID: 6278990
    [No Abstract]   [Full Text] [Related]  

  • 25. [The protective effect of opioid receptor antagonists on acute myocardial ischemia/reperfusion injury in rats].
    Zan XY; Li PJ; Zhang ZY; Tang XQ; Zhao JH; Cao W
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Nov; 19(11):693-4. PubMed ID: 17996143
    [No Abstract]   [Full Text] [Related]  

  • 26. The interaction of phenoxybenzamine with the mouse brain opiate receptor.
    Spiehler V; Fairhurst AS; Randall LO
    Mol Pharmacol; 1978 Jul; 14(4):587-95. PubMed ID: 28470
    [No Abstract]   [Full Text] [Related]  

  • 27. Different receptor sites mediate opioid agonism and antagonism.
    Portoghese PS; Takemori AE
    J Med Chem; 1983 Oct; 26(10):1341-3. PubMed ID: 6312042
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice.
    Waxman AR; Arout C; Caldwell M; Dahan A; Kest B
    Neurosci Lett; 2009 Oct; 462(1):68-72. PubMed ID: 19559072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selectivity of opioid agonists and antagonists for the various opioid receptor types.
    Takemori AE; Portoghese PS
    Psychopharmacol Bull; 1985; 21(3):464-5. PubMed ID: 2994158
    [No Abstract]   [Full Text] [Related]  

  • 30. Electroacupuncture reduces voluntary alcohol intake in alcohol-preferring rats via an opiate-sensitive mechanism.
    Overstreet DH; Cui CL; Ma YY; Guo CY; Han JS; Lukas SE; Lee DY
    Neurochem Res; 2008 Oct; 33(10):2166-70. PubMed ID: 18633703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent developments in the study of opioid receptors.
    Cox BM
    Mol Pharmacol; 2013 Apr; 83(4):723-8. PubMed ID: 23249538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of motropine and of some neuropeptides on opiate receptors.
    Zakusov VV; Bulayev VM
    Ann Ist Super Sanita; 1982; 18(1):7-8. PubMed ID: 6303183
    [No Abstract]   [Full Text] [Related]  

  • 33. Investigations of the preferential reduction in drinking behavior of opiate antagonists.
    Lang IM; Strahlendorf JC; Strahlendorf HK; Lutherer LO; Barnes CD
    Proc West Pharmacol Soc; 1982; 25():293-7. PubMed ID: 7122510
    [No Abstract]   [Full Text] [Related]  

  • 34. Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.
    Portoghese PS; Sultana M; Nagase H; Takemori AE
    J Med Chem; 1988 Feb; 31(2):281-2. PubMed ID: 2828619
    [No Abstract]   [Full Text] [Related]  

  • 35. The bivalent ligand approach in the design of highly selective opioid receptor antagonists.
    Portoghese PS
    NIDA Res Monogr; 1990; 96():3-20. PubMed ID: 2172826
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid opioid detoxification in Australia.
    O'Neil G; Hulse G; Armstrong J; Little M; Murray L
    Acad Emerg Med; 2002 Sep; 9(9):960. PubMed ID: 12208688
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of partial opiate agonists on plasma prolactin and growth hormone levels in the rat.
    Lein EL; Morrison A; Dvonch W
    Life Sci; 1979 Nov; 25(20):1709-15. PubMed ID: 231162
    [No Abstract]   [Full Text] [Related]  

  • 38. [Use of opiate receptor antagonists and peptidase inhibitors for studying central morphinomimetic peptidergic systems].
    Malfroy B
    Ann Endocrinol (Paris); 1983; 44(5):335-7. PubMed ID: 6326657
    [No Abstract]   [Full Text] [Related]  

  • 39. Baclofen, raclopride, and naltrexone differentially affect intake of fat and sucrose under limited access conditions.
    Corwin RL; Wojnicki FH
    Behav Pharmacol; 2009 Sep; 20(5-6):537-48. PubMed ID: 19724193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of kappa opioid receptor agonists on attention as assessed by a 5-choice serial reaction time task in rats.
    Shannon HE; Eberle EL; Mitch CH; McKinzie DL; Statnick MA
    Neuropharmacology; 2007 Dec; 53(8):930-41. PubMed ID: 17959202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.